HPV prophylactic vaccine coverage in France: Results of a survey among high school and university students in marseilles' area;Évaluation de la couverture vaccinale du vaccin anti-hpv: Résultats d'une enquête auprs des lycéennes et étudiantes de la région PACA

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 41, Issue 2, 2012, Pages 136-144

  Sabiani, L ^a   Bremond, A ^b   Mortier, I ^a   Lecuyer, M ^b   Boubli, L ^a,b   Carcopino, X ^a  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cervical cancer; Coverage; Education; HPV prophylactic vaccine; Prevention

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER SCREENING; CYTOLOGY; EDUCATIONAL STATUS; FRANCE; HEALTH EDUCATION; HEALTH STATUS; HEALTH SURVEY; HIGH SCHOOL STUDENT; HUMAN; PHYSICIAN; PROPHYLAXIS; QUESTIONNAIRE; SOCIAL MEDIA; TREATMENT REFUSAL; UNIVERSITY STUDENT; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; FEMALE; FRANCE; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; SCHOOLS; UNIVERSITIES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS;

EID: 84859426630     PISSN: 03682315     EISSN: 17730430     Source Type: Journal    
DOI: 10.1016/j.jgyn.2011.10.001     Document Type: Article

References (26)

1. Institut national du cancer. Dynamique d'évolution des taux de mortalité des principaux cancers en France. INCA; 2010. http://www.e-cancer.fr/./5986-dynamique-devolution-des-taux-de-mortalite-des- principaux-cancers-en-france-novembre-2010 (consulté le 15 mars 2011).
2. Haute Autorité de Santé. État des lieux et recommandations pour le dépistage du cancer du col de l'utérus en France : synthses et recommandations. http://www.has-sante.fr/portail/upload/ docs/application/pdf/2010-11/synthese-recommandations-depistage-cancer-du-col- de-luterus.pdf (consulté le 02 février 2011).
3. Duport N. Données épidémiologiques sur le cancer du col de l'utérus : État des connaissances - actualisations 2008. InVs ; 2008. http://www.invs.sante.fr/publications/2008/cancer-col-uterus-2008/ cancer-col-uterus-2008.pdf (consulté le 22 mars 2011)
4. H. zur Hausen Papillomaviruses and cancer: from basic studies to clinical application Nat Rev 2 2002 342 350 (Pubitemid 37328947)
5. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, and K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 189 1999 12 19 (Pubitemid 29406813)
6. J.L. Pretet, A.C. Jacquard, X. Carcopino, J.F. Charlot, D. Bouhour, and B. Kantelip Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study Int J Cancer 122 2008 428 432 (Pubitemid 350234732)
7. H. zur Hausen Papillomaviruses in the causation of human cancers - a brief historical account Virology 384 2009 260 265
8. F.X. Bosch, M.M. Manos, N. Munoz, M. Sherman, A.M. Jansen, and J. Peto Prevalence of human papillomavirus in cervical cancer: a worldwide perspective international biological study on cervical cancer (IBSCC) Study group J Natl Cancer Inst 87 1995 796 802
9. B. Romanowski, P.C. de Borba, P.S. Naud, C.M. Roteli-Martins, N.S. De Carvalho, and J.C. Teixeira Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years Lancet 374 2009 1975 1985
10. L.R. Medeiros, D.D. Rosa, M.I. da Rosa, M.C. Bozzetti, and R.R. Zanini Efficacy of human papillomavirus vaccines: a systematic quantitative review Int J Gynecol Cancer 19 2009 1166 1176
11. J. Dillner, S.K. Kjaer, C.M. Wheeler, K. Sigurdsson, O.E. Iversen, and M. Hernandez-Avila Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial BMJ 341 2010 c3493
12. ®. Paris : HCSP ; 2008. http://www.hcsp.fr/docspdf/avisrapports/hcspa20101217-ppmvjf1423.pdf (consulté le 07 mars 2011).
13. Haut Conseil de la Santé publique. Avis relatif à la vaccination contre les infections à papillomavirus humains des jeunes filles âgées de 14 à 23 ans. 2010. Paris HCSP ; 2010. http://www.hcsp.fr/docspdf/avisrapports/hcspa20101217-ppmvjf1423.pdf (consulté le 07 mars 2011).
14. D. Riethmuller, J.L. Pretet, F. Denis, F. Aubin, P. Pradat, and C. Clavel Expected impact of a quadrivalent HPV vaccine in France J Gynecol Obstet Biol Reprod 38 2009 389 395
15. Conseil supérieur d'hygine publique de France. Comité technique des vaccinations. Groupe de travail sur la vaccination contre les papillomavirus. 2007. http://www.sante.gouv.fr/htm/dossiers/cshp/r-mt-230307- papillomavirus.pdf (consulté le 20 août 2010).
16. J.P. Fagot, A. Boutrelle, P. Ricordeau, A. Weill, and H. Allemand HPV vaccination in France: uptake, costs and issues for the national health insurance Vaccine 29 2011 3610 3616
17. Dervaux B, Lenne X, Lévy-Bruhl D, Kudjawu Y. Modélisation médico-économique de l'impact du dépistage du cancer du col utérin et de l'introduction de la vaccination contre les HPV dans le calendrier vaccinal. 2007. http://www.ins.sante.fr/publications/2008/ modelisation-hpv/rapport-modelisation-hpv.pdf (consulté le 19 décembre 2010).
18. C. Bergeron, N. Largeron, R. McAllister, P. Mathevet, and V. Remy Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. International journal of technology assessment in health care 2008 Int J Technol Assess Health Care 24 2008 10 19 (Pubitemid 351158538)
19. R.L. Winer, J.P. Hughes, Q. Feng, S. O'Reilly, N.B. Kiviat, and K.K. Holmes Condom use and the risk of genital human papillomavirus infection in young women N Engl J Med 354 2006 2645 2654
20. R.L. Winer, Q. Feng, J.P. Hughes, S. O'Reilly, N.B. Kiviat, and L.A. Koutsky Risk of female human papillomavirus acquisition associated with first male sex partner J Infect Dis 197 2008 279 282 (Pubitemid 351263448)
21. Center for Disease Control Prevention (CDC). National, state, and local area vaccination coverage among adolescents ages 13-17 years - United States 2008 MMWR Morb Mortal Wkly Rep 58 2009 997 1001 http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5932a3.htm (consulté le 25 mars 2011)
22. J.M. Brotherton, S.L. Deeks, S. Campbell-Lloyd, A. Misrachi, I. Passaris, and K. Peterson Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia Commun Dis Intell 32 2008 457 461
23. C.K. Fairley, J.S. Hocking, L.C. Gurrin, M.Y. Chen, B. Donovan, and C.S. Bradshaw Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women Sex Transm Infect 85 2009 499 502
24. Department of health. Annual HPV vaccine uptake in England: 2008/09. http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@en/@ps/ documents/digitalassets/dh-111676.pdf (consulté le 09 septembre 2010).
25. HPV vaccination programme: provisional data, as submitted by PCT's for first and second dose vaccine uptake, for the month ending 28 february 2010. http://www.dh.gov.uk/prod.consum.dh/groups/dh-digitalassets/documents/ digitalassets/dh-115153.pdf (consulté le 09 septembre 2010).
26. P. Arwidson Consommation de soins et de médicaments P. Guilbert, F. Beaudier, A. Gautier, Baromtre de santé 2000 2000 Comité franais d'éducation pour la Santé Paris 311 328